Foghorn Therapeutics (FHTX) Revenue (2020 - 2026)

Foghorn Therapeutics' Revenue history runs 7 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• On a quarterly basis, Revenue fell 45.11% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $28.2 million, a 20.08% increase from a year earlier, with the FY2025 full-year figure at $30.9 million, up 36.75% from the prior year.
• Revenue fell to $3.3 million in Q1 2026 per FHTX's latest filing, from $9.2 million in the prior quarter.
• Across five years, Revenue topped out at $17.5 million in Q3 2023 and bottomed at $2.9 million in Q4 2024.
• The 5-year median for Revenue is $5.8 million (2023), against an average of $6.5 million.
• Across the five-year window, Revenue surged 16080.49% in 2022 and slumped 55.33% in 2024, its largest moves.
• Year by year, Revenue stood at $4.2 million in 2022, then soared by 37.88% to $5.8 million in 2023, then sank by 50.49% to $2.9 million in 2024, then soared by 223.77% to $9.2 million in 2025, then slumped by 64.67% to $3.3 million in 2026.
• Per Business Quant, the three latest FHTX Revenue figures stand at $3.3 million (Q1 2026), $9.2 million (Q4 2025), and $8.2 million (Q3 2025).